



<b>DATE:</b>	2021 October 4
<b>TO:</b>	Calgary Zone Physicians and Healthcare Providers; and APL Managers and Supervisors, MLT II/III, LIC, Accessioning, Clinical Biochemists
<b>FROM:</b>	Clinical Biochemistry, South Sector, Alberta Precision Laboratories (APL)
<b>RE:</b>	<b>ALT and AST Reagent Change and Updated Reference Intervals</b>

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- Effective **October 18, 2021**, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) patient test results are expected to increase by ~15-20% due to a manufacturer reagent reformulation.
- ALT and AST reference intervals are also being harmonized across the province, and the impact of the reagent reformulation is reflected in this change.
- An interim comment will be added to the test report specifying that the updated reference interval reflects provincial harmonization efforts.

### Why this is important

- New ALT and AST reagent reformulation is required for the standardization of ALT and AST patient result interpretation across the Calgary Zone.
- New provincial reference intervals are evidence-based and are derived via statistical analysis of provincial population data. The new reference intervals have been developed to reflect the change in reagent formulation.

### Action Required

- Please be aware of the reagent change and the updates to the reference intervals.

### Inquiries and feedback may be directed to

- Jessica Gifford, PhD, Clinical Biochemist, 403-770-3779, [Jessica.Gifford@albertaprecisionlabs.ca](mailto:Jessica.Gifford@albertaprecisionlabs.ca)

### This bulletin has been reviewed and approved by

- Hossein Sadrzadeh, PhD, FAACC, Clinical Section Chief, Clinical Biochemistry, South Sector
- Paul Klonowski, MD, Associate Medical Director, South Sector, Alberta Precision Laboratories